Canurta Granted First US Patent and Strengthens Québec Industry Partnerships

Canurta Therapeutics Secures First US Patent for Novel Bioactive Polyphenol Extraction Process

We are proud to announce that Canurta has been granted its first US patent for our innovative Bioactive Polyphenol Extraction Process. This milestone validates the novelty and commercial potential of our technology, positioning us uniquely in the biotechnology industry.

This achievement aligns with the recent move in the US towards rescheduling cannabis from Schedule I to III, opening new avenues for medical, pharmaceutical, and research applications. Our patented process allows us to produce naturally derived cannflavins, polyphenols, and other rare ingredients, giving us a significant market advantage.

Learn more about this groundbreaking development and its implications for the future of cannabis research and product innovation in our latest press release:

Read More

Canurta Therapeutics Visits Industry Partners in Québec

We are pleased to share insights from a recent visit to our industry partners, Innofibre Centre d'innovation des produits cellulosiques and CNETE in Québec. Our collaborative project focused on testing and refining methods for the extraction and purification of bioactive compounds from hemp residues on an industrial scale. Our Research Associate and Production Lead participated in a pilot trial that marks a significant milestone achievement.

During this visit, we were also joined by another industry partner, FSOil LLC., who was present for the unveiling of a newly developed process. This visit was instrumental in beginning the transfer of the new and improved extraction processes to our manufacturing partners at FSOil LLC., which will boost the sustainability and efficiency of our production.

Canurta's July Milestones

Bioinformatics

Our bioinformatics team made significant progress in the proteomics analysis of the Answer ALS dataset, marking a significant step forward in our research efforts. Additionally, we initiated the data analysis of the Zebrafish trial, which tested Canurta's CNR-401 formulae's efficacy in an induced ALS model. This provided valuable insights and advanced our understanding of potential treatments for this disease.